MwanzoLXRX • NASDAQ
add
Lexicon Pharmaceuticals Inc
$ 1.59
Baada ya Saa za Kazi:(0.0063%)-0.00010
$ 1.59
Imefungwa: 2 Apr, 20:00:00 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 1.64
Bei za siku
$ 1.58 - $ 1.63
Bei za mwaka
$ 0.36 - $ 1.83
Thamani ya kampuni katika soko
673.65M USD
Wastani wa hisa zilizouzwa
2.71M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 5.49M | -79.31% |
Matumizi ya uendeshaji wa biashara | 63.59M | -42.09% |
Mapato halisi | -15.53M | 54.01% |
Kiwango cha faida halisi | -282.72 | -122.33% |
Mapato kwa kila hisa | -0.04 | 55.56% |
EBITDA | -14.66M | 53.47% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 96.23M | -59.56% |
Jumla ya mali | 184.99M | -38.01% |
Jumla ya dhima | 77.45M | -49.20% |
Jumla ya hisa | 107.54M | — |
hisa zilizosalia | 423.68M | — |
Uwiano wa bei na thamani | 5.47 | — |
Faida inayotokana na mali | -18.90% | — |
Faida inayotokana mtaji | -20.82% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -15.53M | 54.01% |
Pesa kutokana na shughuli | -17.23M | 19.81% |
Pesa kutokana na uwekezaji | 4.83M | -91.01% |
Pesa kutokana na ufadhili | -2.93M | -2,714.42% |
Mabadiliko halisi ya pesa taslimu | -15.33M | -147.75% |
Mtiririko huru wa pesa | -11.59M | -25.13% |
Kuhusu
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1995
Tovuti
Wafanyakazi
81
